CeriBell (NASDAQ:CBLL) Receives $32.50 Average Price Target from Brokerages

Shares of CeriBell (NASDAQ:CBLL) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $32.50.

A number of brokerages recently weighed in on CBLL. Canaccord Genuity Group restated a “buy” rating and set a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on CeriBell in a research note on Friday, April 4th. They issued a “buy” rating and a $32.00 price target for the company.

CeriBell Stock Performance

Shares of CBLL stock opened at $16.58 on Friday. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75. The stock’s fifty day simple moving average is $17.06 and its 200 day simple moving average is $21.98.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.49 million for the quarter, compared to the consensus estimate of $19.30 million. On average, equities analysts anticipate that CeriBell will post -2.46 EPS for the current year.

Insider Activity

In related news, CEO Xingjuan Chao sold 5,700 shares of the company’s stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00. Following the sale, the chief executive officer now owns 746,451 shares in the company, valued at $11,211,694.02. This represents a 0.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders sold 49,700 shares of company stock valued at $796,434. Company insiders own 20.10% of the company’s stock.

Institutional Investors Weigh In On CeriBell

Institutional investors and hedge funds have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in shares of CeriBell during the 4th quarter valued at about $32,000. Summit Investment Advisors Inc. bought a new position in CeriBell in the fourth quarter worth approximately $33,000. Tower Research Capital LLC TRC bought a new position in CeriBell in the fourth quarter worth approximately $37,000. BNP Paribas Financial Markets bought a new position in CeriBell in the fourth quarter worth approximately $43,000. Finally, PNC Financial Services Group Inc. bought a new position in CeriBell in the fourth quarter worth approximately $47,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.